β³ Fetching live dividend data...
Home βΊ Calculator βΊ SSYNF Dividend Calculator 2026
Sensyne Health plc Β· OTC
Price: $0.00 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in SSYNF β $1.0010004501200205e+38M in 10 years Β· $8,340,836,334,033,435,000,000,000,000,000,000,000,000,000.00/month
Sensyne Health plc, a healthcare technology company, develops software products that connects healthcare professionals with patients in the United Kingdom and the United States. Its products include CVm-Health, a web-based application for Covid-19 self-monitoring; DBm-Health, a patient to clinician system that allows health care professionals manage patients with diabetes; GDm-Health, a prescribed digital therapeutic for remote management of diabetes in pregnancy; and BPm-Health that allows pregnant women to self-monitor blood pressure during pregnancy. The company's products also include MagnifEye that allows reading and analysis of diagnostic tests; SEND, an evidence-based digital charting system for vital-signs observations; EDGE, a prescribed digital therapeutic for monitoring chronic obstructive pulmonary disease at home; CleanSpace, a system for monitoring personal exposure to air pollution; Support-HF, a prescribed digital therapeutic for monitoring heart failure at home; Sense, a clinical AI algorithm engine; SYNE-COV, a COVID-19 patient outcome algorithm; and SYNE-OPS, a real-time operational patient management algorithm. Sensyne Health has strategic research alliance with Bayer and Roche; collaboration agreement with Alexion to study the prevalence and outcomes of patients in certain disease areas; research collaboration agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research; research agreement with University of Oxford to conduct a multi-omics drug discovery research project in asthma; strategic research agreement with Milton Keynes University Hospital, Somerset, Hampshire, Royal Wolverhampton, and Royal Devon and Exeter NHS Trusts. Sensyne Health plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. Β· Privacy Policy
Ready to invest? Open SSYNF position with:
Real after-tax yield depends on where you live and how you hold SSYNF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 1000000.00% | 999997.20% | $100,000,000 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 850000.00% | 849997.20% | $85,000,000 / yr |
| πΊπΈ US Taxable (20%) | 20% | 800000.00% | 799997.20% | $80,000,000 / yr |
| π¬π§ UK ISA | 0% | 1000000.00% | 999997.20% | $100,000,000 / yr |
| π¬π§ UK Taxable | 8.75% | 912500.00% | 912497.20% | $91,250,000 / yr |
| π¨π¦ TFSA | 0% | 1000000.00% | 999997.20% | $100,000,000 / yr |
| π¨π¦ CA Taxable | 25% | 750000.00% | 749997.20% | $75,000,000 / yr |
| π¦πΊ Super (pension) | 15% | 850000.00% | 849997.20% | $85,000,000 / yr |
| π¦πΊ AU Taxable | 30% | 700000.00% | 699997.20% | $70,000,000 / yr |
| π©πͺ DE Taxable | 26.375% | 736250.00% | 736247.20% | $73,625,000 / yr |
| π«π· FR Taxable | 30% | 700000.00% | 699997.20% | $70,000,000 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
SSYNF pays quarterly β 4 times per year. Next ex-div: TBD.
How SSYNF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for SSYNF sourced from FMP /financial-growth endpoint β real data, not estimates.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the SSYNF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β
Real users. No sign-up required to leave a review.
βFinally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.β
βI've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly β $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.β
βReally solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.β
βAs someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.β
βThe Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.β
Reviews reflect users' personal experiences. Not financial advice.
Leave a review β